Quantcast

Latest Non-alcoholic fatty liver disease Stories

2014-08-27 08:24:05

MarketOptimizer.org adds new clinical trial report "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" to its store. DALLAS, Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global Clinical Trials Review, H2, 2014 provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site...

2014-08-06 08:31:42

PORTLAND, Oregon, August 6, 2014 /PRNewswire/ -- A new report by Allied Market Research entitled, "Nonalcoholic Steatohepatitis Market (Pipeline analysis, drug class and Geography) Global Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", indicates that the global nonalcoholic steatohepatitis (NASH) market would reach $1.6 billion by 2020 registering CAGR of 25.6% from 2014 to 2020. The high prevalence of Type II diabetes and obesity, which lead...

2014-07-21 10:59:26

Massachusetts General Hospital Daily treatment with tesamorelin for six months lowered liver fat modestly but significantly The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. In a paper that will appear in the July 23/28 issue of JAMA – a theme issue on HIV/AIDS receiving early online release to coincide with...

2014-07-08 12:28:47

TEL AVIV, Israel, July 8, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial manuscript, entitled "The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease," provides the full report of the Phase IIa trial, which was...

2014-07-01 16:29:45

NY Times Article Brings Attention to Dangerous Lifestyle Related Epidemic and Suggests Critical Need for Therapy DENVER, July 1, 2014 /PRNewswire/ -- A recent New York Times article ("Threat Grows from Liver Illness Tied to Obesity", June 13 2014) alerting millions to the growing prevalence and seriousness of fatty liver disease revealed a stark and very concerning reality about therapeutic options. There are currently no drugs approved for either NAFLD (nonalcoholic fatty liver...

2014-06-23 09:37:29

Monash University An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease. Type 2 diabetes and non-alcoholic fatty liver disease are key complications of obesity as 80 per cent of patients with type 2 diabetes are obese, and 75 per cent of patients who are obese or have type 2 diabetes also have fatty liver disease. The team, led by Professor Tony Tiganis from the Department...

2014-06-23 08:28:45

Company Presents Positive Preclinical Efficacy Results at ICE/ENDO 2014 Meeting RALEIGH, N.C., June 23, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin),...

2014-06-04 15:37:59

Washington University in St. Louis Studying mice, researchers have found a way to prevent nonalcoholic fatty liver disease, the most common cause of chronic liver disease worldwide. Blocking a path that delivers dietary fructose to the liver prevented mice from developing the condition, according to investigators at Washington University School of Medicine in St. Louis. The study appears in a recent issue of The Journal of Biological Chemistry. In people, nonalcoholic fatty liver...

2014-05-12 20:23:17

Dr. Michael Feiz has helped countless patients overcome such issues as obesity-related fatty liver disease LOS ANGELES, May 12, 2014 /PRNewswire/ -- People with fatty liver problems who may be considering a gastric sleeve or lap band in Beverly Hills with Dr. Michael Feiz have some new information to consider. A study of the effect of bariatric procedures on NAFLD (non-alcoholic fatty liver disease) has proven to be another weight loss surgery testimonial alongside recent evidence...

2014-05-12 08:31:08

DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease pipeline assets - Adds to Shire's rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire's already strong Gastrointestinal (GI) presence - Adds LUM001 in Phase 2 development for four rare and devastating hepatic diseases, two...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.